Otenzepad

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameOtenzepad
Drug Alias Nameotenzepadum奥腾泽帕otenzepad奥腾折帕AF-DX-116BS +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M2 antagonists
TargetsMuscarinic acetylcholine receptor M2
Therapy Area/IndicationsBradycardiaArrhythmias, Cardiac
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsBradycardiaArrhythmias, Cardiac

Other Information

ATC CodeN/A
Related LinksN/A